에 대한 최신 뉴스 Twist Bioscience (NASDAQ:TWST) 주식

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Mid Cap

News

Movers

ALHC

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 1. 쾨르 마이닝(NYSE:CDE)의 주식은 36.59% 상승했다. 이 회사는 네바다주에 확장된 로체스터(Rochester) 은-금 광산의 처리량 추세가 긍정적이라고 보고했다.

쾨르 마이닝, 뉴 골드 및 RH는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 8일-9월 14일)

Equities

Markets

$BTC

ARKF

ARKW

AVAV

DKNG

GLBE

RDDT

RKLB

STNE

TWLO

TWOU

수요일에 캐시 우드의 아크 인베스트(Ark Invest)는 몇 가지 중요한 거래를 했다. 그 중 가장 눈에 띄는 것은 쇼피파이(NYSE:SHOP), 레딧(NYSE:RDDT)의 주식 매수, 그리고 코인베이스 글로벌(NASDAQ:COIN)의 주식 매각이다.

아크 인베스트는 쇼피파이 주식 $3,000만 이상 매입, 레딧도 매수, 코인베이스 주식은 매도

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

<p>In the latest quarter, 4 analysts provided ratings for Aspen Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $244.25, a high estimate of $260.00, and a low estimate of $217.00. Surpassing the previous average price target of $211.50, the current average has increased by 15.48%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840494_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Aspen Technology among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Mark Schappel</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$217.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Aspen Technology. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aspen Technology compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Aspen Technology's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Aspen Technology's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AZPN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Aspen Technology analyst ratings.</strong></a></p>
<h2>Delving into Aspen Technology's Background</h2>
<p>Aspen Technology is a global leader in asset optimization software, enabling customers within capital-intensive industries to design, operate and maintain their functions to meet their profitability, safety, and sustainability goals. The heritage business of AspenTech was founded in 1981 and provides software solutions purposed to optimize engineering, manufacturing, and supply chain and asset management functions. In 2021, Emerson Electric traded over $6 billion in cash and its Open Systems International (digital grid management) and subsurface science and engineering businesses for 55% of AspenTech's shares. The new AspenTech is the combination of heritage Aspen, OSI, and SSE and serves more than 3,000 customers across 40 countries.</p>
<h3>Aspen Technology's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Aspen Technology displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>6.94%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Aspen Technology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>13.04%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Aspen Technology's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.35%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.32%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.01</strong>, Aspen Technology adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

AZPN

Aspen Technology Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<p>Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) has outperformed the market over the past 5 years by 20.14% on an annualized basis producing an average annual return of 33.43%. Currently, Freeport-McMoRan has a market capitalization of $67.35 billion. </p>
<p><strong>Buying $100 In FCX:</strong> If an investor had bought $100 of FCX stock 5 years ago, it would be worth <strong>$407.07</strong> today based on a price of $46.87 for FCX at the time of writing.</p>
<h3>Freeport-McMoRan's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840471_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

$100 Invested In Freeport-McMoRan 5 Years Ago Would Be Worth This Much Today

<p>Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) has outperformed the market over the past 20 years by 1.87% on an annualized basis producing an average annual return of 10.07%. Currently, Charles Schwab has a market capitalization of $129.11 billion. </p>
<p><strong>Buying $1000 In SCHW:</strong> If an investor had bought $1000 of SCHW stock 20 years ago, it would be worth <strong>$7,028.16</strong> today based on a price of $70.58 for SCHW at the time of writing.</p>
<h3>Charles Schwab's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840466_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SCHW

Here's How Much $1000 Invested In Charles Schwab 20 Years Ago Would Be Worth Today

<p>Across the recent three months, 6 analysts have shared their insights on DigitalBridge Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for DigitalBridge Gr, revealing an average target of $17.83, a high estimate of $23.00, and a low estimate of $16.00. Observing a downward trend, the current average is 8.56% lower than the prior average price target of $19.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840463_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive DigitalBridge Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ric Prentiss</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Richard Choe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Niknam</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ric Prentiss</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DigitalBridge Gr. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DigitalBridge Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of DigitalBridge Gr's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of DigitalBridge Gr's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DBRG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on DigitalBridge Gr analyst ratings.</strong></a></p>
<h2>Delving into DigitalBridge Gr's Background</h2>
<p>DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.</p>
<h3>DigitalBridge Gr: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> DigitalBridge Gr's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-71.02%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> DigitalBridge Gr's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-1.16%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> DigitalBridge Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-0.07%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> DigitalBridge Gr's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.03%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> DigitalBridge Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.29</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DBRG

A Closer Look at 6 Analyst Recommendations For DigitalBridge Gr

<p>In the preceding three months, 11 analysts have released ratings for Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $228.27, a high estimate of $250.00, and a low estimate of $219.00. This upward trend is apparent, with the current average reflecting a 3.95% increase from the previous average price target of $219.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840451_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Waste Management is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$231.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Coleman</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Jeffrey Goldstein</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$227.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Kevin Chiang</td>
<td>CIBC</td>
<td>Raises</td>
<td>Neutral</td>
<td>$228.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$220.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Stephanie Yee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$226.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$220.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Konark Gupta</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$220.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Waste Management. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Waste Management compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Waste Management's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Waste Management's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Waste Management analyst ratings.</strong></a></p>
<h2>Discovering Waste Management: A Closer Look</h2>
<p>WM ranks as the largest integrated provider of traditional solid waste services in the United States, operating 263 active landfills and about 332 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.</p>
<h3>Waste Management: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Waste Management's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>7.91%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Waste Management's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>13.55%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>9.85%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.21%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Waste Management's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.09</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


11 Analysts Have This To Say About Waste Management

<p>Ratings for Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Indie Semiconductor, presenting an average target of $8.75, a high estimate of $12.00, and a low estimate of $7.00. Observing a downward trend, the current average is 18.6% lower than the prior average price target of $10.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730840415_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Indie Semiconductor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ross Seymore</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Suji Desilva</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Indie Semiconductor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Indie Semiconductor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Indie Semiconductor's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Indie Semiconductor's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/INDI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Indie Semiconductor analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Indie Semiconductor: A Closer Look</h2>
<p>Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for advanced Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.</p>
<h3>Unraveling the Financial Story of Indie Semiconductor</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Indie Semiconductor displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>0.47%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Indie Semiconductor's net margin excels beyond industry benchmarks, reaching <strong>-36.6%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Indie Semiconductor's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-4.24%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Indie Semiconductor's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.39%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Indie Semiconductor's debt-to-equity ratio is below the industry average at <strong>0.39</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


INDI

Key Takeaways From Indie Semiconductor Analyst Ratings

<p><a href="https://www.bloomberg.com/news/articles/2024-11-05/golub-capital-combines-four-clos-into-biggest-reset-on-record">https://www.bloomberg.com/news/articles/2024-11-05/golub-capital-combines-four-clos-into-biggest-reset-on-record</a></p>
<p>Asset manager Golub Capital issued the largest reset of a collateralized loan obligation on record late last <a href="https://www.bloomberg.com/news/terminal/SM8MWAT0G1KW">week</a>, created through an amalgamation of multiple CLOs.</p>
<p>Golub fused four different CLOs together, a type of transaction that's been performed <a href="https://www.bloomberg.com/news/terminal/Q5AINZT0G1KZ">at least once before</a>. Its combination formed a massive $2.2 billion reset, surpassing a $2 billion <a href="https://www.bloomberg.com/news/terminal/QPD0N5T1UM11">record </a>previously set by Antares in 2021, according to data from <a href="https://www.bloomberg.com/quote/JPM:US">JPMorgan Chase &amp; Co.</a></p>


GBDC

'Golub Capital Combines Four CLOs Into Biggest Reset On Record; The $2.2B Deal Surpasses Formerly Largest Antares Reset; Nearly $30B Of CLO Resets Priced In October 2024' - Bloomberg News

<p><a href="https://www.bloomberg.com/news/articles/2024-11-05/apple-to-face-first-eu-fine-under-bloc-s-digital-markets-act">https://www.bloomberg.com/news/articles/2024-11-05/apple-to-face-first-eu-fine-under-bloc-s-digital-markets-act</a></p>
<p>Apple Inc. is set to face the first-ever fine under the European Union's new digital antitrust rules for Big Tech, representing an escalation of a clash with regulators over the dominance of its hugely profitable App Store.</p>


Legal

AAPL

'Apple To Face First EU Fine Under Bloc's Digital Markets Act' - Bloomberg News

<p>By Doug Young</p>
<p><strong>Yum China Holdings Ltd.</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yumc#NYSE">YUMC</a>) announced on Monday it will boost its spending on repurchasing its shares and paying dividends, as it continued to deliver solid revenue and core operating profit growth of 5% and 18%, respectively, in the third quarter despite a challenging operating environment. It said the results demonstrated the effectiveness of its strategy and ability to outperform in a challenging and fluid environment.</p>
<p>Yum China also said it was further raising its cash allocation for share buybacks and dividends, often referred to by companies as &ldquo;returning value to shareholders,&rdquo; to $4.5 billion over the three years from 2024 to 2026 from a previous commitment of $3 billion.</p>
<p>The company has already spent nearly three times as much on shareholder returns in the first nine months of this year as it did in the same period last year, including over $1 billion in share repurchases and $187 million in quarterly dividends.</p>
<p>Yum China has continually repurchased its shares since it was spun off from its former parent,&nbsp;<strong>Yum Brands&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yum#NYSE">YUM</a>) in 2016. The company has grown rapidly since Yum opened its first KFC in Beijing in 1987, and it is now the country&rsquo;s largest restaurant operator.</p>
<p>While share buybacks provide value to shareholder by reducing the size of a company&rsquo;s outstanding shares, Yum China said it canceled its repurchased shares, which is more beneficial to shareholder than other treatment. Yum China has bought back more than 27 million shares this year, around 7% of its total shares outstanding. That has helped its earnings per share (EPS) to grow more quickly than actual profit growth, with its EPS up 33% in this year&rsquo;s third quarter, ahead of the 22% rise in its actual net profit for the period.</p>
<p>Yum China&rsquo;s cumulative shareholder returns have exceeded $4 billion since it first listed in the U.S. in 2016. It picked up the pace sharply after making a second listing in Hong Kong in 2020. Yum China&rsquo;s cash position remains healthy, with net cash of $3.1 billion at the end of September. &nbsp;</p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.</em></p>


Asia

General

YUMC

NEWS WRAP: Yum China Boosts Returns To Shareholders On Strong Quarterly Results

<p>Suze Orman, a well-known personal finance expert, has a simple but powerful message: Small spending habits can snowball into big financial setbacks. Over time, the decisions we make about seemingly insignificant purchases end up costing us hundreds or even thousands of dollars. According to Orman, learning to say &#8220;no&#8221; to our loved ones as well as to ourselves is one of the most difficult things.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually,</strong><a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor"><strong> </strong><strong>here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</strong></a></li>
<li><strong>This Jeff Bezos-backed startup will allow you to</strong><a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"><strong> </strong><strong>become a landlord in just 10 minutes, and you only need $100</strong></a><strong>.</strong></li>
</ul>
<h2 class="wp-block-heading">The Little Mistakes That Add Up</h2>
<p>Orman often discusses the hidden costs of our everyday spending habits. Grabbing a name-brand item or a small impulse buy at the grocery store may not seem like much in the moment, but a few extra dollars each trip quickly adds up to hundreds or even thousands annually.&nbsp;</p>
<p>The problem isn&#8217;t limited to groceries. Orman also points out how easy it is to let spending on other non-necessities slip by – buying individually wrapped snacks instead of in bulk, for example.&nbsp;</p>
<p><strong>Trending: Can you guess how many retire with a $5,000,000 nest egg? </strong><a href="https://www.benzinga.com/money/5mil-nest-egg-adv"><strong>The percentage may shock you</strong></a><strong>.</strong></p>
<h2 class="wp-block-heading">Why Cutting Back Matters</h2>
<p>You might think, &#8220;I work hard; I deserve to splurge a little.&#8221; While there's truth to wanting to reward yourself, Orman urges people to think about what's really at stake. The more you spend on things you don&#8217;t truly need, the less you have for what's important – emergencies, retirement or peace of mind.</p>
<p>In one of her examples, Orman recalls <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/10/41553671/the-wealthy-follow-suze-ormans-golden-rule-for-getting-rich-she-says-theres-1">buying a modest apartment</a> when she could have afforded a million-dollar penthouse. For her, the key was buying what she needed, not just what she could afford. It's a lesson she wishes more people would consider: focus on your needs, not your wants. Otherwise, the unexpected can leave you struggling financially.</p>
<p><strong>Trending: </strong><a href="https://www.benzinga.com/money/100k-cd"><strong>$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</strong></a></p>
<h2 class="wp-block-heading">Say &#8220;No&#8221; To Loved Ones (And Yourself)</h2>
<p>Saying &#8220;no&#8221; is hard, especially when it comes to family. But Orman believes it&#8217;s crucial if you&#8217;re serious about meeting your financial goals. You need the discipline to recognize when you're spending just because you can and know when that money could be better used elsewhere.</p>
<p>Orman isn't the only one with opinions on spending habits. The same is true for one of the wealthiest people on the planet, Warren Buffett, who is known for driving secondhand cars and <a href="https://www.benzinga.com/news/24/09/41107810/billionaire-warren-buffett-still-lives-in-an-old-corner-house-he-purchased-for-32k-i-couldnt-imagine">living in a modest home</a>. His prudence reminds us that living below our means can pave the way for long-term financial success.</p>
<p><strong>See Also: The average American couple has saved this much money for retirement —</strong><a href="http://www.benzinga.com/money/smartasset"><strong> </strong><strong>How do you compare</strong></a><strong>?</strong></p>
<h2 class="wp-block-heading">Gen Z&#8217;s Take on Money</h2>
<p>Orman has also offered her thoughts on Gen Z&#8217;s financial practices, arguing that they often place excessive <a href="https://www.benzinga.com/personal-finance/24/09/40778796/suze-orman-says-gen-zs-fashion-obsession-hinders-wealth-building-they-would-rather-dress-cool-go">emphasis on appearances rather than investing</a>. But not every expert agrees. While younger generations may spend money on social media influence or new clothing, many are also beginning to invest earlier than prior generations. They use social media platforms like TikTok and YouTube to build income streams, turning their creativity into cash.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Studies show 50% of consumers think Financial Advisors cost much more than they do —</strong><a href="https://www.benzinga.com/money/money-pickle"><strong> </strong><strong>to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</strong></a></li>
<li><strong>Many are using this retirement income calculator to check if they&#8217;re on pace —</strong><a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"><strong> </strong><strong>here&#8217;s a breakdown on how on what&#8217;s behind this formula.</strong></a></li>
</ul>


Personal Finance

If You Do This, Prepare To Spend Thousands On Non-Necessities, Says Suze Orman. Her Solution? Learn To Say "No" To Loved Ones

WIIM

THTX

Foghorn Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.

MediaAlpha shares are trading lower following a report from Wolfpack Research.

<p>Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 52 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 44% leaning bullish and 50% bearish. Among these notable options, 16 are puts, totaling $721,919, and 36 are calls, amounting to $2,134,986.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $480.0 to $650.0 for UnitedHealth Group during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for UnitedHealth Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UnitedHealth Group's whale trades within a strike price range from $480.0 to $650.0 in the last 30 days. </p>
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730839752_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.05</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$567.50</td>
<td>$278.8K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">173</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.15</td>
<td>$17.1</td>
<td>$17.1</td>
<td>$565.00</td>
<td>$237.6K</td>
<td style="text-align: right;">187</td>
<td style="text-align: right;">158</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$14.95</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$565.00</td>
<td>$145.0K</td>
<td style="text-align: right;">148</td>
<td style="text-align: right;">241</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$11.05</td>
<td>$10.7</td>
<td>$11.05</td>
<td>$562.50</td>
<td>$102.7K</td>
<td style="text-align: right;">50</td>
<td style="text-align: right;">127</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$19.3</td>
<td>$19.2</td>
<td>$19.3</td>
<td>$557.50</td>
<td>$88.5K</td>
<td style="text-align: right;">174</td>
<td style="text-align: right;">97</td>
</tr>
</tbody>
</table>
</p>
<h3>About UnitedHealth Group</h3>
<p>UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.</p>
<h3>Where Is UnitedHealth Group Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,471,322, the price of UNH is up by 1.84%, reaching $568.04.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $637.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $644.<br />
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on UnitedHealth Group with a target price of $650.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650.<br />
&#x2A; An analyst from RBC Capital persists with their Outperform rating on UnitedHealth Group, maintaining a target price of $595. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for UnitedHealth Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

A Closer Look at UnitedHealth Group's Options Market Dynamics

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Cassava Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SAVA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Cassava Sciences.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 18% bullish and 54%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $179,025, and 7 are calls, for a total amount of $351,889.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $60.0 for Cassava Sciences over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cassava Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cassava Sciences's significant trades, within a strike price range of $15.0 to $60.0, over the past month.</p>
<h3>Cassava Sciences Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730839747_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.95</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$45.00</td>
<td>$104.6K</td>
<td>1.9K</td>
<td style="text-align: right;">134</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.45</td>
<td>$7.75</td>
<td>$7.76</td>
<td>$15.00</td>
<td>$77.5K</td>
<td>2.3K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.95</td>
<td>$10.9</td>
<td>$10.9</td>
<td>$45.00</td>
<td>$71.9K</td>
<td>1.9K</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.0</td>
<td>$8.7</td>
<td>$8.7</td>
<td>$60.00</td>
<td>$43.4K</td>
<td>2.2K</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.0</td>
<td>$8.5</td>
<td>$8.7</td>
<td>$60.00</td>
<td>$42.6K</td>
<td>2.2K</td>
<td style="text-align: right;">153</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cassava Sciences</h3>
<p>Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.</p>
<p>After a thorough review of the options trading surrounding Cassava Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Cassava Sciences</h3>
<ul>
<li>With a volume of 1,410,319, the price of SAVA is down -7.39% at $23.93. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What Analysts Are Saying About Cassava Sciences</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $116.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a positive move, an analyst from HC Wainwright &amp; Co. has upgraded their rating to Buy and adjusted the price target to $116. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Cassava Sciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


SAVA

Unpacking the Latest Options Trading Trends in Cassava Sciences

<p>Financial giants have made a conspicuous bullish move on Iovance Biotherapeutics. Our analysis of options history for Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 45% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $234,150, and 5 were calls, valued at $414,807.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.5 to $15.0 for Iovance Biotherapeutics during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Iovance Biotherapeutics's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Iovance Biotherapeutics's whale activity within a strike price range from $7.5 to $15.0 in the last 30 days. </p>
<h3>Iovance Biotherapeutics Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730839741_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.3</td>
<td>$10.00</td>
<td>$141.9K</td>
<td>2.4K</td>
<td style="text-align: right;">433</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$9.00</td>
<td>$135.0K</td>
<td>6.1K</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.5</td>
<td>$1.2</td>
<td>$1.49</td>
<td>$15.00</td>
<td>$64.8K</td>
<td>891</td>
<td style="text-align: right;">440</td>
</tr>
<tr>
<td>IOVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.9</td>
<td>$12.00</td>
<td>$46.8K</td>
<td>109</td>
<td style="text-align: right;">362</td>
</tr>
<tr>
<td>IOVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$12.00</td>
<td>$45.6K</td>
<td>109</td>
<td style="text-align: right;">242</td>
</tr>
</tbody>
</table>
</p>
<h3>About Iovance Biotherapeutics</h3>
<p>Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.</p>
<p>Following our analysis of the options activities associated with Iovance Biotherapeutics, we pivot to a closer look at the company's own performance.</p>
<h3>Iovance Biotherapeutics's Current Market Status</h3>
<ul>
<li>With a volume of 1,428,846, the price of IOVA is down -1.97% at $11.21. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What The Experts Say On Iovance Biotherapeutics</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $17.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from UBS lowers its rating to Buy with a new price target of $17.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Iovance Biotherapeutics options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


IOVA

Iovance Biotherapeutics Options Trading: A Deep Dive into Market Sentiment

Reported Earlier, Roku 13G Filing Shows Sumitomo Mitsui Trust Group, Inc. Reported A 5.06% Stake In The Co As Of September 30, 2024

<p><a href="https://www.reuters.com/business/autos-transportation/stellantis-ceo-did-not-confirm-maserati-ev-plans-union-says-2024-11-05/">https://www.reuters.com/business/autos-transportation/stellantis-ceo-did-not-confirm-maserati-ev-plans-union-says-2024-11-05/</a></p>
<p>Stellantis CEO Carlos Tavares has failed to confirm previously announced electrification plans for Maserati, Italian trade unionists said after meeting him on Tuesday, adding to concern about the loss-making luxury brand.</p>
<p>Tavares visited Maserati's plant in its hometown of Modena, but "no clear answers came" from his conversations with workers' representatives, Samuele Lodi and Stefania Ferrari of the FIOM-Cgil union said in a joint statement.</p>
<p>Lodi and Ferrari expressed concern that "contrary to what was previously communicated" to unions, the planned start of production in mid-2025 of the electric version of the MC 20 sports car was not mentioned.</p>
<p>"There was no mention of electric models, nor of other new models coming to the Modena plant," they said.</p>
<p>Tavares came to Modena with the new CEO of Maserati Santo Ficili, appointed this month.</p>
<p>Under its previous boss, Maserati announced plans to fully electrify its lineup by 2028, including with a new version of its Levante large SUV in 2027, and a new Quattroporte luxury sedan in 2028.</p>
<p>The Franco-Italian automaker has repeatedly denied speculation about a possible sale of Maserati, although Tavares has said the group cannot afford to keep brands that are not profitable.</p>
<p>Stellantis was not available for comment on the union statement.</p>
<p>In a note earlier on Tuesday it said it was pushing ahead with electrification and "finalising a strategic plan to take the (Maserati) brand back to the top of the sector, with a full pipeline of new products and technologies for the coming years".</p>


STLA

'Stellantis CEO Did Not Confirm Maserati EV Plans, Union Says' - Reuters News

<p><a href="https://www.reuters.com/legal/google-defeats-lawsuit-over-gift-card-fraud-2024-11-05/#:~:text=Nov%205%20(Reuters)%20%2D%20A,of%20dollars%20stolen%20from%20victims.">https://www.reuters.com/legal/google-defeats-lawsuit-over-gift-card-fraud-2024-11-05/#:~:text=Nov%205%20(Reuters)%20%2D%20A,of%20dollars%20stolen%20from%20victims.</a></p>
<p>A federal judge dismissed a proposed class action lawsuit accusing Google of illegally profiting from Google Play gift card scams by refusing to refund millions of dollars stolen from victims.</p>
<p>In a late Monday decision, U.S. District Judge Beth Labson Freeman said the plaintiff Judy May lost money because scammers induced her to buy gift cards, and failed to show that Google caused her losses or knew it was receiving stolen funds.</p>
<p>The San Jose, California-based judge also said Google was not liable for keeping 15% to 30% commissions on purchases that scammers made with the gift cards, because Google's conduct was unrelated to the original fraud.</p>
<p>May said she lost $1,000 in April 2021 when a scammer posing as a relative instructed her to contact a supposed government agent, who told her she was eligible for federal grant money if she bought Google Play gift cards.</p>
<p>The Brownsville, Indiana resident said she provided the codes on the back to cover supposed upfront costs, but the scammers used the codes to make purchases.</p>
<p>May said she would not have bought the cards had Google warned on the packaging about scams, and that anyone demanding payment with the cards was a scammer.</p>
<p>Lawyers for May did not immediately respond on Tuesday to requests for comment. Google, a unit of Alphabet, did not immediately respond to similar requests.</p>
<p>Freeman said May could try to refile her lawsuit, but dismissed a claim seeking triple damages for good. Alphabet is based in Mountain View, California.</p>
<p>In 2023, Americans lost $217 million in <a href="https://www.ftc.gov/system/files/ftc_gov/pdf/CSN-Annual-Data-Book-2023.pdf">gift card or reload card fraud, opens new tab</a>, according to the Federal Trade Commission.</p>
<p>The actual amount is likely much higher because the data cover only reported cases. Citing FTC data from 2021, May said Google Play cards account for about 20% of gift card scams.</p>
<p>&nbsp;</p>
<p>The case is May v Google LLC et al, U.S. District Court, Northern District of California, No. 24-01314.</p>


GOOG

GOOGL

Reported Earlier, "Google Defeats Lawsuit Over Gift Card Fraud" - Reuters News

<p><strong>Fox Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) warrants a Buy rating, according to <strong>Goldman Sachs</strong> analyst Michael Ng.</p>
<p>On Monday, Fox reported <a href="https://www.benzinga.com/news/earnings/24/11/41715564/foxs-q1-earnings-revenue-and-eps-beat-political-ads-tubi-expansion-boosts-growth" target="_blank" rel="noreferrer noopener">fiscal first-quarter 2025</a> revenues of $3.56 billion, up from $3.21 billion a year ago, beating the analyst consensus of $3.37 billion. </p>
<p>Ng  maintains a <a href="https://www.benzinga.com/quote/FOXA/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $46 to $51</a>.</p>
<p>Cable Network Programming reported quarterly segment revenues of $1.6 billion, up by 15%. Television reported quarterly segment revenues of $1.95 billion, up 10%.</p>
<p><strong>Also Read:</strong> <a href="https://www.benzinga.com/news/earnings/24/11/41714051/marriott-international-q3-earnings-china-market-weakness-drags-on-performance-adjusts-full-year-out" target="_blank" rel="noreferrer noopener">Marriott International Q3 Earnings: China Market Weakness Drags on Performance, Adjusts Full-Year Outlook</a></p>
<p>Ng observed that Fox Corp outperformed in the first quarter of fiscal 2025, reporting EBITDA of $1.05 billion, above the expected $874 million consensus. This was driven largely by stronger-than-anticipated results in both its Cable Network Programming segment, which posted an EBITDA of $748 million, and its Television segment, which delivered $372 million.</p>
<p>The analyst attributed the Cable Network's success to operating expense control and Fox News Media's ratings. At the same time, Television gained from higher-than-expected political ad revenues, notably in local stations and the streaming platform Tubi, which grew 19% year-over-year.</p>
<p>He raised Fox's 12-month price target to $51 from $46, reflecting expectations of record political ad revenue for fiscal 2025 as Tubi's ad performance strengthens.</p>
<p>Ng highlighted Tubi's targeted advertising appeal in the FAST (free ad-supported streaming) category. He expects the platform to benefit from continued political ad spending.</p>
<p>Fox Corp anticipates Tubi's revenue to exceed $1 billion in fiscal 2025. That projection aligns with market estimates, underscoring the platform's long-term growth potential as digital ad budgets shift.</p>
<p><strong>Price Action:</strong>&nbsp;FOXA stock is up 1.73% at $43.75 at&nbsp;the last check on Tuesday.</p>
<p><strong>Now Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/11/41710271/roaring-kitty-stock-chewy-set-to-join-s-p-midcap-400-index-will-replace-stericycle" target="_blank" rel="noreferrer noopener">Roaring Kitty Stock Chewy Set to Join S&amp;P MidCap 400 Index, Will Replace Stericycle</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Price Target

Reiteration

FOXA

Fox Corp's Political Ad Revenue Surges, Tubi Growth Sparks Analyst Optimism

<p><strong>Tesla, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has reportedly introduced a new incentive to promote car purchases to capitalize on <a target="_blank" href="https://www.benzinga.com/news/24/11/41738613/elon-musk-rejects-rumors-of-a-tesla-phone-but-says-the-ev-giant-will-have-to-make-one-if-this-happen" rel="noreferrer noopener">China's auto consumption stimulus.</a></p>
<p>The EV giant is offering Chinese customers the chance to win a tour of its Giga Shanghai, <a target="_blank" href="https://cnevpost.com/2024/11/05/tesla-shanghai-plant-visit-as-purchase-incentive/" rel="noreferrer noopener">reported</a> CnEV Post.</p>
<p>The report, citing a post on Weibo, said that from now until December 3, those who order a new vehicle through the official trade-in program and take delivery within the contract period will be eligible.</p>
<p>Teslarati <a target="_blank" href="https://www.teslarati.com/tesla-china-giga-shanghai-tour-incentive/" rel="noreferrer noopener">reports</a> that ten winners will be selected for a special tour of Gigafactory Shanghai by December 3. Each winner can bring a friend and receive free round-trip airfare and one night's hotel accommodation.</p>
<p>In October, the gigafactory in Shanghai touched a new production milestone of 3 million cars.</p>
<p><strong>Related: <a target="_blank" href="https://www.benzinga.com/news/24/10/41303692/teslas-giga-shanghai-hits-3-million-production-milestone-celebrates-with-red-model-rollout" rel="noreferrer noopener">Tesla's Giga Shanghai Hits 3 Million Production Milestone, Celebrates With Red Model Rollout</a></strong></p>
<p>Tesla had made the announcement via social media <a target="_blank" href="https://x.com/Tesla_Asia/status/1844709411983655249" rel="noreferrer noopener">platform</a> X.</p>
<p>"Giga Shanghai achieves 3 million production milestone," the company wrote with an adjoining image of the employees at the gigafactory in China celebrating the milestone with a red Tesla car in their midst.</p>
<p>Tesla China's Gigafactory Shanghai is the EV giant's largest by production volume, with an estimated annual output exceeding 950,000 vehicles, according to the third quarter 2024 Update Letter, Teslarati added. Giga Shanghai manufactures the Model 3 and Model Y for both the domestic Chinese market and international markets.</p>
<p>Meanwhile, Tesla has reportedly raised wages for all its employees at&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/giga-berlin" rel="noreferrer noopener">its gigafactory in Berlin</a>. Reuters reported that the wage hike has been in effect since the start of November. The factory in Berlin employs nearly 12,000 staff.</p>
<p>The Berlin factory is Tesla's only in Europe. Its current installed annual vehicle capacity is over 375,000 Model Ys.</p>
<p><strong>Price Action: </strong>TSLA shares are trading higher by 4.39% to $253.13&nbsp;at the last check on Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/11/41741441/tesla-hikes-wages-by-4-for-giga-berlin-employees-report" target="_blank" rel="noreferrer noopener">Tesla Hikes Wages By 4% For Giga Berlin Employees: Report</a></strong></li>
</ul>
<p><em>Photo by betto rodrigues on Shutterstock</em></p>


Emerging Markets

Tesla Lures Chinese Buyers With Exclusive Giga Shanghai Tour Giveaway to Boost Sales: Report

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.&nbsp;</p>



<p>Investors raced to sell off their stock and repay their loans, causing markets to crash.&nbsp; A weaker market allows investors to purchase stock at discounted prices. Indeed, the Healthcare sector is positioned to grow to $819 billion by 2027 at a robust 7% CAGR. One of the strongest growing sectors within the industry is health tech from generative AI use cases in the space.</p>



<p>Investors should take advantage of current market conditions and buy these Healthcare <a href="https://investorplace.com/industries/technology/artificial-intelligence/">AI stocks</a>.</p>



<h2>Twist Bioscience (TWST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/11/twst1600-300x169.png" alt="Scientific handling a light microscope examines a laboratory sample for pharmaceutical bioscience research. Concept of science, laboratory and study of diseases. Twist Biosciences (TWST)"><div>Source: dhvstockphoto / Shutterstock.com</div></div><p><strong>Twist BioScience</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/twst-stock-quote/"><strong>TWST</strong></a></span>) is a biotechnology company that manufactures synthetic DNA products. <a href="https://finance.yahoo.com/quote/VST/analysis/"><em>Yahoo! Finance</em></a> reports seven analysts predicting a 1-year price range on TWST between $31.11 and $65.00, with an average price target of $51.91.&nbsp;</p>



<p>TWST reported financials that are characteristic of a biotechnology company. Q2 2024 revenue was strong, growing 27.81% YOY. However, the company has yet to return a profit this quarter, which has continued for the past year. There has been a trend of decreasing assets for the company, with total assets decreasing by 21.25% for Q2 2024. This marks the biggest decrease in the past year. However, the company&rsquo;s improving liquidity offers hope to investors. A 464.11% increase in free cash flow for Q2 2024 demonstrates management handling operational expenses.&nbsp;</p>



<p>The company may have a reversal in the future from a partnership with bitBiome. Both companies partnered to create an enzyme screening kit with pharmaceutical applications. The enzyme (transaminase) within the kit is specialized in synthesizing active pharmaceutical ingredients while serving as an environmentally safe alternative to other methods. TWST recently <a href="https://www.businesswire.com/news/home/20240604321380/en/Twist-Bioscience-Announces-Participation-in-Department-of-Commerce-Consortium-Dedicated-to-AI-Safety">joined</a> the U.S. AI Safety Institute Consortium (ASIC) to promote ethical AI development. Being environmentally and ethically conscious with upside potential makes TWST one of the healthcare AI stocks to buy.</p>



<h2>GE Healthcare (GEHC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/gehc1600-300x169.png" alt="GE Healthcare (GEHC) sign. GE Healthcare is an American company founded in 2014 and spun off from GE in 2023."><div>Source: testing / Shutterstock.com</div></div><p><strong>GE Healthcare</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gehc-stock-quote/"><strong>GEHC</strong></a></span>) is a healthcare company that provides digital infrastructure, data analytics and decision support tools for various healthcare applications. <a href="https://finance.yahoo.com/quote/GEHC/analysis/"><em>Yahoo! Finance</em></a> reports 17 analysts predicting a 1-year price range on GEHC between $84.00 and $105.00, with an average price target of $93.95.&nbsp;</p>



<p>GEHC has solid financials for Q2 2024. The company barely missed on revenue but beat EPS expectations for the quarter. Revenue grew <a href="https://www.google.com/finance/quote/GEHC:NASDAQ">0.46%</a> year over year, and net profit margin grew 1.84% year over year. Additionally, management has improved its handling of operational expenditures, with free cash flow growing 131.81% year over year.&nbsp;</p>



<p>GEHC could be primed for a breakout with an <a href="https://aws.amazon.com/blogs/industries/aws-and-ge-healthcare-are-teaming-up-to-use-ai-to-improve-patient-care/">AWS partnership</a>. GEHC has partnered with <strong>Amazon</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/amzn-stock-quote/"><strong>AMZN</strong></a></span>) to develop AI models for healthcare applications. Specifically, the partnership aims to aggregate data from doctor notes, x-rays and other medical tests to develop healthcare insights. For instance, compositing data in such a manner streamlines future similar processes by establishing precedents of solutions and treatments. The potential this AWS partnership carries, alongside strong financials, makes GEHC one of the Healthcare AI stocks to watch.</p>



<h2>Clover Health (CLOV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/clov_clover_health_1600-300x169.png" alt="Clover Health (CLOV) company logo on a website with blurry stock market developments in the background, seen on a computer screen through a magnifying glass."><div>Source: Dennis Diatel / Shutterstock.com</div></div><p><strong>Clover Health </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/clov-stock-quote/"><strong>CLOV</strong></a></span>) is a healthcare company that provides Medicare Advantage insurance plans and operates as a direct contracting entity of the US government. <a href="https://finance.yahoo.com/quote/CLOV/analysis/">Yahoo Finance!</a> reports three analysts covering the stock with one buy rating and two hold ratings for July 2024.</p>



<p>CLOV reported very strong financials for Q2 2024. While revenue grew by <a href="https://www.google.com/finance/quote/CLOV:NASDAQ">7%</a>, the net profit margin grew by 75.33%. Moreover, this quarter marks the first quarter of positive net income for the company. As a result of such good earnings, management has improved full-year guidance. The level of improvement is best seen through EBITDA projections. Originally, EBITDA guidance was between a $20 million loss and gain; now, it is between $50 and $65 million.</p>



<p>The company has developed Clover Assistant, an AI assistant SaaS. The assistant is meant to serve as a clinical decision-making tool for payers and providers based on the patient&rsquo;s medical and financial data. Furthermore, the assistant tool allows CLOV to expand in areas that Medicare Advantage doesn&rsquo;t reach. It also has the potential for one-on-one use with Medicare Advantage patients as a recurring revenue stream on a use-by-use basis. Developments with AI and an improving financial outlook make CLOV one of the <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> for investors to consider.</p>



<p><em>On the date of publication, Matthew Rodrigues&nbsp;<em>did not hold (either directly or indirectly) any positions in the securities mentioned in this article.</em>&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div><p>Matthew Rodrigues is a college student studying Business at UC Berkeley Haas. He believes detailed research and correct interpretation of current events is what leads to investment success.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/3-healthcare-ai-stocks-positioned-for-potential-breakthroughs/">3 Healthcare AI Stocks Positioned for Potential Breakthroughs</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Healthcare AI Stocks Positioned for Potential Breakthroughs

Invesco Main Street Small Cap Fund Q2 2024 Review

Invesco Small Cap Growth Fund Q2 2024 Review

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CureVac (CVAC – Research Report), Vericel (VCEL – Research Report...

Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)

Interest Rate Regimes And ARKG: Underperformance Explained

Barclays analyst Luke Sergott maintained a Buy rating on Twist Bioscience (TWST – Research Report) today and set a price target of $55.00. The comp...

Barclays Sticks to Their Buy Rating for Twist Bioscience (TWST)

Analyst Catherine Ramsey Schulte of Robert W. Baird maintained a Buy rating on Twist Bioscience (TWST – Research Report), retaining the price targe...

Positive Outlook and Strong Pricing Strategy Justify Buy Rating for Twist Bioscience

XOMA Royalty Corporation (XOMA) has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation (TWST) to acquire...

Xoma enters $15M royalty monetization arrangement with Twist Bioscience

Twist Bioscience enters into purchase agreement with XOMA Royalty

Leerink Partners analyst Puneet Souda maintained a Hold rating on Twist Bioscience (TWST – Research Report) on October 22. The company's shares ope...

Leerink Partners Remains a Hold on Twist Bioscience (TWST)

ACHC

ADMA

ATKR

BLFS

CLOV

CRDO

CVAC

CYRX

CYTK

DAVA

EXAS

FRSH

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

GEHC

GKOS

GLOB

GTES

GTLB

GWRE

INSP

ITGR

ITRI

KNSL

LSCC

MANH

MTSI

NTLA

ONON

ONTO

PACB

PFSI

PYCR

PZZA

RARE

RGEN

RMBS

SDGR

SITE

SITM

SKWD

SMCI

TMDX

TMXXF

VCEL

WING

XOMA

Press Releases

Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Twist Bioscience to Present at Baird Global Healthcare Conference 2024

Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels

Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance

Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024

Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Comments

Twist Bioscience

뉴스

에 대한 최신 뉴스 Twist Bioscience (NASDAQ:TWST) 주식

금요일, 11월 01, 2024

월요일, 9월 16, 2024

목요일, 5월 09, 2024

수요일, 5월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌